Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy [0.03%]
双特异性和多特异性T细胞接头分子：推动免疫治疗的未来进展
Xiaoqiang Kang,Yue Zhao,Hong Ling et al.
Xiaoqiang Kang et al.
T-cell engagers (TCEs) represent an emerging class of immunotherapies that harness T cells' cytotoxic power to eliminate diseased cells-a transformative future therapeutic strategy. TCEs form immunological synapses to trigger potent immune ...
The development of a next generation NK cell engager platform by integrating a potency-reduced IL-15 variant to enhance antitumor activity [0.03%]
通过整合活性降低的IL-15变异体来增强抗肿瘤活性的下一代NK细胞衔接平台的发展
Lijun Wang,Yinhui Ding,Huifeng Lv et al.
Lijun Wang et al.
Background: Natural killer cell engager (NKCE) has gained attention recently. Conventional NKCEs exhibit mild anti-tumor efficacy despite acceptable safety profiles. Therefore, next-generation NKCE development is essentia...
RO4, a high-affinity humanized antibody against the juxtamembrane region of mesothelin for targeted cancer therapy [0.03%]
靶向癌症治疗的人源化单克隆抗体RO4：针对间皮素膜附近区域的高亲和力抗体
Masanori Onda,Xiufen Liu,Wenlong Liu et al.
Masanori Onda et al.
Background: Mesothelin (MSLN) is a surface antigen highly expressed in several solid tumors, including mesothelioma, ovarian, and pancreatic cancers. However, therapeutic efficacy of MSLN-targeted agents is often compromi...
Unique loop-structured CD19/CD22 bispecific CAR-T-cell therapy for patients with relapsed/refractory diffuse large B-cell lymphoma: an observational study [0.03%]
针对复发/难治性弥漫大B细胞淋巴瘤患者的独特环状结构CD19/CD22双特异性CAR-T细胞疗法：一项观察性研究
Shuhong Li,Liqiong Liu,Zelin Liu et al.
Shuhong Li et al.
Background: Although CD19 and CD22 chimeric antigen receptor (CAR-T) cell therapies have demonstrated encouraging clinical responses in patients with B-cell lymphoma, over 50% of patients ultimately experience disease pro...
Recent advances in structural investigations of cancer antigen mesothelin and its interactions with therapeutic antibodies [0.03%]
近年肿瘤抗原mesothelin结构及与治疗性抗体相互作用研究进展
Jingyu Zhan,Mitchell Ho,Lothar Esser et al.
Jingyu Zhan et al.
The tumor-associated antigen mesothelin is highly expressed in many human cancers, while its expression in normal tissues is limited. Its interaction with the cancer antigen 125 promotes heterotypic cell adhesion and tumor metastasis. Mesot...
Integrative and Emerging Models in Antibody Research: A Comprehensive Review [0.03%]
抗体研究中的综合与新兴模型：全面综述
Jagadeeswara Reddy Devasani,Girijasankar Guntuku,Prathyusha Sarabu et al.
Jagadeeswara Reddy Devasani et al.
Antibody research has advanced through the integration of in vivo, in vitro, and in silico models, each offering distinct advantages and limitations. In vivo models, such as traditional animal models and humanized mouse models, provide crit...
Overcoming antigen tolerance to develop GB22-45-2, an anti-DKK1 antibody for gastric cancer [0.03%]
克服抗原耐受性以开发用于胃癌的抗DKK1抗体GB22-45-2
Wenjun Zhang,Xiling Wei,Tianqi Yao et al.
Wenjun Zhang et al.
Background: Gastric cancer (GC) represents one of the most prevalent and lethal malignancies, however, current treatments have shown limited efficacy. Clinical investigations have revealed that Dickkopf-1 (DKK1)-high GC p...
Assessing the therapeutic potential of a panel of novel VCAM-1 antibodies using microfluidic and three-dimensional in vitro models of vascular inflammation [0.03%]
采用微流体和体内血管炎症模型评估新型VCAM-1抗体治疗潜力
Jessica R Pickett,Lucia F Zacchi,Binura Perera et al.
Jessica R Pickett et al.
Objective: Antibodies against vascular cell adhesion molecule (VCAM)-1 represent an attractive strategy for atherosclerosis and cardiovascular disease management due to their ability to selectively block leukocyte-endothe...
Engineering a novel light-chain single-domain antibody to enable IgG-format bispecific antibody design [0.03%]
工程化新型轻链单域抗体以实现IgG格式双特异性抗体设计
Mingkai Wang,Qingyuan Xu,Yu Kong et al.
Mingkai Wang et al.
Background: As one of the most promising classes of next-generation antibody therapeutics, bispecific antibodies (bsAbs) have gained increasing attention owing to their unique dual-targeting mechanisms. However, current b...
Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase [0.03%]
靶向前列腺特异性膜抗原和前列腺酸性磷酸酶的新型高亲和力全人源抗体的产生与表征
Claudia Comacchio,Stefanie K Pfister,Domenico Ravazza et al.
Claudia Comacchio et al.
Background: Prostate-specific membrane antigen (PSMA)-targeted therapies have revolutionized the management of patients with prostate cancer. However, not all patients benefit from such agents. Prostatic acid phosphatase ...